Theracryf PLC Share Chat (TCF)

Net cash (30 April 2024) c£3m - current market cap and zero factored in for any IP

"The company has also conducted an interventional phase 1b study establishing good safety and tolerability, strong dose-related target engagement and strong correlation between dosage and improvement of autism severity standardized scores (ABC, SRS) with a manuscript currently under review."

Presumably we wait for the review and then we know one way or the other, Stalicla do seem to be pushing forward on several fronts so perhaps it's simply a case of prioritization...

Davey, if TCF announced Stalicla have paid the $500k that they disputed and they anticipate the $5m in the coming months that would send the share price rising by probably up to 200%, which was why I bought in again. But it’s not looking very likely. It’s unclear how much cash reserves TCF. They issued that share placing recently but by my calculations it was used to acquire this new company. It’s a gamble but it could pay very well if the news is encouraging.

I'm actually thinking of buying in, Val did over 100% on news recently so this is looking very bombed out and easy for any little sale to really drop the price atm so it might be a good time to buy..might be

I’ve sold out, that’s my trade at 08:27. Another loss made on this share.

I didn’t have a lot invested here. I lost £3300 when I sold out at 2.55p in the back end of last year. I bought approx 200,000 shares at about 0.85p in February. I know it’s not much but I don’t want to lose it, I’m here to make money, I would like to just experiment with this money now to see if I can make it grow with short term trading on shares which release good RNS’s each day.

I bought in after the dispute notice was issued, confident that there was an oversight or some small detail which EVG overlooked to meet the requirements of the milestone payment, after all EVG had stated they expected up to $5.5m this year in milestone payments and Stalicla stated on their website that this would go into phase 2 this year.

However clearly it’s not some small oversight, 15 weeks have passed without any update or news. As DSFlat pointed out, there are no updates on the data analysis by Stalicla and even Stalicla removed from their website that this would go into phase 2 this year. Doesn’t that say it all?

Everything has been so quiet on SFX-01, so little news in the last year. TCF cannot afford to do clinical trials on their main asset and no one is signing deals to trial it for their potential own gain. Everything seems to have dried up, with not a penny of income in the last 12 months.

The acquisition of the new company even feels like they ran out of work with SFX-01 and they have had to shelve their plans.

I sold my holding but it had to go to a negotiated order, again not a good sign when you can’t get prices to sell as they did give a price to buy.

Today is the last trading day before full results, uninspiring results could see this drop further, but positive encouraging results could see this rise. But can it really be positive given the year they’ve had?

It has been a rotten year, the share price is a disaster. We thought 2p was low, now we would need to see a rise of 300% just to get there. In one of the QnA’s last year they talked about wanting to get shareholder value, well they are not doing a very good job on it.

What a disappointment this share has proved to be.

Many thanks, CJ

Not utter despair then, but not too hopeful either. Back in the bottom drawer

My guess is that Stalicla wanted to tie up SFX-01 (medical grade Sulforaphane) but test using a non synthetic Sulforaphane to establish a benchmark.

By entering into the agreement with Evgen they could presumably then look into using other readily available forms of Sulforaphane and compare results, cost analysis and future product protection i.e Patent longevity with SFX-01 or alternative solutions.

Perhaps even considering a production of their own Sulforaphane product ?

Theracryf not reporting on the recent Stalicla test results isn't encouraging for me and might suggest SFX-01 hasn't been used in testing at all.

Are Stalicla waiting for better patient diagnostics as mentioned in their paper ? With the WaveDancer, Firefly Neuroscience merger playing a part in their commercialization strategy ?

We've got a new name, new products, we just need a new CEO ;-)

Mcco, it has been nothing short of a disaster in the last 18 months here. After they announced the Stalicla deal in Oct 2022 which was worth $163m in milestone payments plus royalties, they had £10m in the bank, $6m to be received from Stalicla in 2023, Juvenesense deal was soon to go commercial, loads of things happening with SFX-01 trials, hopes of signing new deals, you can see why so many people bought in. But since then the following has happened: only $500k received from Stalicla, the $5.5m to be received in 2023 has still yet to be received, EVG/TCF issued a dispute notice 15 weeks ago to say that they believe they are owed $500k but we have heard absolutely nothing. Juvenesense deal ended before it went commercial, no real explanation given why Juve pulled the plug. The £10m has basically run out and a share placing was issued diluting the shares. No new deals signed for SFX-01. Hardly any news on SFX-01 trails. Are we close to SFX-01 going to go commercial? No, it’s a million miles off. Not sure of the current cash position but annual results are due out next week. I think we are all pleased for that as TCF never keep shareholders updated.

The only hope we have is that Stalicla have not pulled the plug, if they pay the $5.5m it will help but how long before any further money comes in? It’s not good here but its not over just yet, a stream of positive news could see this share price get back into the 2-3p range.

SORRY ,a misreading of “results of the AGM “ shown in the RNS lists is dared 31 October 2017 and refers to another TCF

Not de-listing news. No idea where that poster got that idea from.

In due course, when they can no longer get any more raises away, sure. More likely than not, by some margin of probability, IMO, but not right now.

They have some cash, but presumably this R&D event is going to try and get some more interest for, I would imagine, another round of dilution, to extend the lifestyle runway. But I could be wrong of course :) GLA.

Where was the delisting news? Directors participated in latest raise at 1p, not huge but did buy some.

Https://theracryf.com/wp-content/uploads/2024/05/CaptialAccessGroup_TheraCryf.pdf

This share had gone off my radar since the name change but now see that my original investment at 7.685 is now only worth ten per cent of that and judging by recent contributions here, there does not seem much optimism and I also see that we are due to be delisted later in the year

I also see that there have been zero purchases by directors in almost ten years

Thank goodness that the final results are due, I bet the board would say nothing to the shareholders about the Stalicla deal progress for another six months otherwise. Don’t expect too much positive news, TCF have not received a single penny of income in the last year apart from the share placing. I can’t believe how the news here has totally dried up. You never hear anything about SFX-01 nowadays.

Why would they not stump up the (according to Evgen BOD now overdue) cash payment, with all the potential risks that such a move might entail, if they were satisfied with our product? If it is that good, they run the risk of someone else snapping it up and leaving them with a lost opportunity?

Why don't you give Stal a call and let us know what they say.

The level of trust most people have in the BOD here now is commensurate with their history, IMO.

Anyway, 8 days for some greater clarity. It would of course be good to hear from the BOD where things stand on Stal before then, but I am not holding my breath. GLA.

Why would Stallicia enter into a contract with a company to acquire the rights to use its primary asset, Sulforaphane, and then not use that product in its own trials?

And yet, not enough interest, it seems, to make the payment that the company feel Stal owes us now. But which the BOD has informed us is being disputed.

Seemingly no other interest from any other party, including big pharma, to enter into a JV, or make an outright offer for, well anything here.

Which is why we are where we are and presumably why several of the main shareholders chose to be diluted, rather than retain their size of position here, after the highly dilutive raise.

The solubility bioavailability and stability of SFX-01 makes it superior to other forms of sulforaphanes .Hence the interest from Stalicla ?

SFX-01, also known as Sulforadex®, is a synthetic form of sulforaphane that is stabilized by an alpha-cyclodextrin ring. The alpha-cyclodextrin (Alfadex) is therapeutically inert and has a lipophilic core which stabilizes the lipophilic sulforaphane1. This makes it overall water-soluble, which greatly enhances the bioavailability and stability of sulforaphane

Yes, that is precisely my opinion on the reason for the acquisition.

I think they will try and present the idea of 'compelling' material that they say they think will 'deliver outstanding shareholder value'...'exciting data' and other similar words and phrases to that effect, as they pretty much did on the last one.

Try and get more funding to advance that stuff and keep the payroll in place for another year or so, if they can.

Possibly all in the same RNS that basically says it is game over without additional shareholder support (fresh money). Perhaps even in the same RNS that expresses 'surprise and disappointment' that Stal have now pulled the plug, despite tireless communication with them, or that Stal have put in place additional stipulations which mean essentially the same reality for existing shareholders and the balance sheet.

But look, I could be entirely wrong and all could be fine and dandy.

Either way, I presume they will have to give a black and white update in the year end results, whenever they are. I forget now the specific date for this.

'The compound is unstable in solutions, freshly prepared is recommended.'

https://www.medchemexpress.com/Sulforaphane.html

Presumably Stalicla are replicating the tests using SFX-01 to compare data...

"Overall, our results support the use of integrative systems biology toward the characterization of mechanistically defined and clinically actionable subgroups in ASD and the corresponding tailored treatments. Lastly, this approach paves the way for precision medicine-based drug discovery in NDDs."

Looking at the publication it looks like Sulforaphane was a success ( I'm not a medical expert ;) but the Sulforaphane used wasn't SFX-01 ?

Any further share placings will 100% mean it’s game over for shareholders here. I’m not sure how long the company is funded until, we will find out in the coming weeks when we get the year end results. They will surely be forced to give an update on the Stalicla deal in that.

You do have to wonder what all of the staff are doing for their salary. Is this why they acquired the new company as they had run out of work to do with SFX-01. All work on the drug is being done externally.

We need positive news about the Stalicla deal asap to turn this share around.

Yes, pretty much. And Stalicla are only partially to blame - and only if they are pulling a fast one, rather than the BOD here being guilty of failing to meet the disputed end points for further cash payments. After Juv, lack of BOD inside buying spanning years, whilst awarding themselves rock star remuneration long before it could be justified (or affordable)....well, Stalicla might be blame-free, who knows?

I wonder if they will manage to get another raise away next time? I would rather this went pop and they lost their generous income stream here, rather than keep the lights on for a few more years. Shareholder value is never going to be realised here. Not with this BOD. Maybe not with any BOD. IMO of course, although the probabilities are strongly in favour of it being so, unfortunately.

Yes in hindsight no one connected to EVG buying shares does seem significant now. To make out repeatedly that they would love to but can’t for legal reasons that they couldn’t go into is quite bizarre. It really does now appear that it was a made up excuse to avoid answering why they didn’t want to answer why they didn’t want to buy in.

Have you given up all hope here LWHL? I was confident after the dispute notice was issued that all would be resolved, afterall to put in a dispute notice made me feel confident that EVG had fulfilled their requirements and even on the Stalicla website at the time it said this would go into phase 2 in 2024. But almost 14 weeks have past and no news, whilst Stalicla removed from their website that this would go into phase 2 this year. Why would they remove that? I don’t know what is going on here but this Stalicla deal has cost us all dearly. I think most people here bought in because of this deal and after 19 months all EVG/TCF have received is $500k, not enough to fund the company more than 2 months.

While you should never buy or sell from a post on a chat board, dismissing bear opinions simply because you are long something is asking for a lesson in individual money contraction!

I was long and wrong here for too long really, but I never entirely dismissed the bear posters; I did pay less attention to those who appeared too intense and repetitive in their negativity, or those who veered from bear to bull for no seemingly strong reason. But, like today, when I am long something, I pay particular attention to the considered bear posts.

Probably even more so now, after a few soakings. And AIM is for the occasional short term punt, never a long term hold investment, as far as I am concerned now. Unlike a few years ago.

And especially if a BOD do not buy big from their own pocket, like the lifestyle ones here.

Most recent evidence to support this thesis/opinion, especially in this particular space: VAL and even CREO.